Article

Moore named Iridex interim president, CEO

William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.

Mountain View, CA-William M. Moore has been named interim president and chief executive officer (CEO) of Iridex Corp. Moore succeeds Dominik Beck, whose employment with the company ceased Aug. 24.

Moore will continue to serve as chairman of the Iridex board of directors during his tenure as interim CEO. He has served as a director of the company since September 2007.

Moore co-founded Natus Medical Inc. in 1990 and served as CEO until 1993. He still serves on the Natus board of directors. Moore also served as a consultant to BlueLine Partners, a private equity firm and investor in Iridex, from February 2004 until June 2008.

Iridex also announced that the board has appointed James Mackaness as chief operating officer, effective immediately. He will continue to serve in his role as the company’s chief financial officer.

In assuming the president and CEO role, Moore indicated that he will lead Iridex’s strategic direction and execution to increase shareholder value, whereas Mackaness will assume more day-to-day operational responsibilities.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.